The critical role of macrophages in the pathogenesis of hidradenitis suppurativa

[1]  P. Riis,et al.  Patients with hidradenitis suppurativa have no increased risk of Alzheimer disease , 2017, The British journal of dermatology.

[2]  A. Kouris,et al.  Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients , 2017, International journal of dermatology.

[3]  A. Banerjee,et al.  Interferon-gamma (IFN-γ) is Elevated in Wound Exudate from Hidradenitis Suppurativa , 2017, Immunological investigations.

[4]  G. Carretero Hernández,et al.  Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients , 2017, The Journal of dermatological treatment.

[5]  C. Antoniou,et al.  Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1‐year follow‐up , 2016, Clinical and experimental dermatology.

[6]  S. Walsh,et al.  Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. , 2016, Journal of the American Academy of Dermatology.

[7]  H. Kato,et al.  Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra , 2016, Case reports in rheumatology.

[8]  Y. Lévy,et al.  Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. , 2016, The Journal of investigative dermatology.

[9]  A. Gottlieb,et al.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. , 2016, The New England journal of medicine.

[10]  C. Zouboulis,et al.  Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder? , 2016, Reviews in Endocrine and Metabolic Disorders.

[11]  G. Jemec,et al.  Cyclosporine treatment of severe Hidradenitis suppurativa – A case series , 2016, The Journal of dermatological treatment.

[12]  J. Boer.  Resolution of hidradenitis suppurativa after weight loss by dietary measures, especially on frictional locations , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  E. Prens,et al.  Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients , 2016, The British journal of dermatology.

[14]  T. Giner,et al.  Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa , 2016, The British journal of dermatology.

[15]  E. Prens,et al.  An Update on Medical Treatment Options for Hidradenitis Suppurativa , 2016, Drugs.

[16]  P. Horvatovich,et al.  Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum , 2016, The British journal of dermatology.

[17]  C. Sweeney,et al.  Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa , 2015, The British journal of dermatology.

[18]  V. Kraus,et al.  Colchicine--Update on mechanisms of action and therapeutic uses. , 2015, Seminars in arthritis and rheumatism.

[19]  E. Prens,et al.  Pathophysiology of hidradenitis suppurativa: An update. , 2015, Journal of the American Academy of Dermatology.

[20]  G. Jemec,et al.  The bacteriology of hidradenitis suppurativa: a systematic review , 2015, Experimental dermatology.

[21]  A. Gottlieb,et al.  Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial , 2015, The British journal of dermatology.

[22]  J. Ingram,et al.  Management of hidradenitis suppurativa: a U.K. survey of current practice , 2015, The British journal of dermatology.

[23]  B. Strober,et al.  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.

[24]  M. Lebwohl,et al.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.

[25]  K. Reich,et al.  A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. , 2015, The New England journal of medicine.

[26]  Haitao Guo,et al.  Inflammasomes: mechanism of action, role in disease, and therapeutics , 2015, Nature Medicine.

[27]  J. Gilmer,et al.  Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update , 2015, Mediators of inflammation.

[28]  J. Lapins,et al.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[29]  O. Borghi.  Association of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Shares Genetic and Cytokine Profiles With Other Autoinflammatory Diseases: Erratum , 2015, Medicine.

[30]  E. Prens,et al.  Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. , 2015, Journal of the American Academy of Dermatology.

[31]  K. Schroder,et al.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases , 2015, Nature Medicine.

[32]  P. A. Crawford,et al.  Ketone body β-hydroxybutyrate blocks the NLRP3 inflammasome-mediated inflammatory disease , 2015, Nature Medicine.

[33]  I. Ceccherini,et al.  Association of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Shares Genetic and Cytokine Profiles With Other Autoinflammatory Diseases: Erratum , 2015, Medicine.

[34]  A. Alavi,et al.  Quality-of-Life Impairment in Patients with Hidradenitis Suppurativa: A Canadian Study , 2015, American Journal of Clinical Dermatology.

[35]  M. Ziman,et al.  A Systematic Review and Meta-Analysis of Strength Training in Individuals With Multiple Sclerosis Or Parkinson Disease , 2015, Medicine.

[36]  J. Szepietowski,et al.  Bacteriology of hidradenitis suppurativa - which antibiotics are the treatment of choice? , 2014, Acta dermato-venereologica.

[37]  Kaibo Duan,et al.  Human Dermal CD14+ Cells Are a Transient Population of Monocyte-Derived Macrophages , 2014, Immunity.

[38]  D. Pandhi,et al.  Biologics in Dermatology: An Integrated Review , 2014, Indian journal of dermatology.

[39]  J. Kirby,et al.  Health care utilization patterns and costs for patients with hidradenitis suppurativa. , 2014, JAMA dermatology.

[40]  S. García-Rodicio,et al.  Ustekinumab for hidradenitis suppurativa: a case report. , 2014, Actas dermo-sifiliograficas.

[41]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[42]  Y. Poulin,et al.  Interleukin 17A: toward a new understanding of psoriasis pathogenesis. , 2014, Journal of the American Academy of Dermatology.

[43]  P. Mortimer,et al.  Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention , 2014, Clinical and experimental dermatology.

[44]  R. Peebles,et al.  Th17-mediated inflammation in asthma. , 2013, Current opinion in immunology.

[45]  E. Latz,et al.  Activation and regulation of the inflammasomes , 2013, Nature Reviews Immunology.

[46]  C. Morton,et al.  Diagnosis and management of hidradenitis suppurativa , 2013, BMJ : British Medical Journal.

[47]  G. Jemec,et al.  Depression in patients with hidradenitis suppurativa , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[48]  G. Plewig,et al.  Impaired Notch‐MKP‐1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology , 2013, Experimental dermatology.

[49]  D. Conte,et al.  Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy , 2013, Inflammatory bowel diseases.

[50]  M. Simpson,et al.  γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. , 2013, The Journal of investigative dermatology.

[51]  G. Jemec,et al.  Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. , 2013, Acta dermato-venereologica.

[52]  E. Giamarellos‐Bourboulis,et al.  Impact of Toll‐like receptor‐4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa , 2013, The British journal of dermatology.

[53]  P. Wolf,et al.  Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis , 2013, PloS one.

[54]  A. Kimball,et al.  Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa , 2012, Annals of Internal Medicine.

[55]  L. Stingeni,et al.  Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A. , 2012, Journal of the American Academy of Dermatology.

[56]  E. Prens,et al.  Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa , 2012, Annals of the rheumatic diseases.

[57]  Yanyun Zhang,et al.  Expression of the CD11c gene in subcutaneous adipose tissue is associated with cytokine level and insulin resistance in women with polycystic ovary syndrome. , 2012, European journal of endocrinology.

[58]  M. Simpson,et al.  Mutations in the γ-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). , 2012, The Journal of investigative dermatology.

[59]  J. Laman,et al.  Can Animal Skin Diseases or Current Transgenic Mice Serve as a Model for Hidradenitis Suppurativa? , 2012, Dermatology.

[60]  W. Gulliver,et al.  Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[61]  P. Stoodley,et al.  Considering hidradenitis suppurativa as a bacterial biofilm disease. , 2012, FEMS immunology and medical microbiology.

[62]  L. Hooper,et al.  Epithelial antimicrobial defence of the skin and intestine , 2012, Nature Reviews Immunology.

[63]  R. Fernández-torres,et al.  Long-term efficacy of infliximab in hidradenitis suppurativa , 2012, The Journal of dermatological treatment.

[64]  Prerna Bhargava,et al.  Role and function of macrophages in the metabolic syndrome. , 2012, The Biochemical journal.

[65]  L. Wancket,et al.  Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. , 2012, Life sciences.

[66]  J. Laman,et al.  Adalimumab (antitumour necrosis factor‐α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study , 2012, The British journal of dermatology.

[67]  J. Laman,et al.  Alterations in leucocyte subsets and histomorphology in normal‐appearing perilesional skin and early and chronic hidradenitis suppurativa lesions , 2012, The British journal of dermatology.

[68]  Nan Li,et al.  Notch Signal Suppresses Toll-like Receptor-triggered Inflammatory Responses in Macrophages by Inhibiting Extracellular Signal-regulated Kinase 1/2-mediated Nuclear Factor κB Activation* , 2011, The Journal of Biological Chemistry.

[69]  G. Folkerts,et al.  Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. , 2011, European journal of pharmacology.

[70]  A. Armstrong,et al.  Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms , 2011, The British journal of dermatology.

[71]  N. Yawalkar,et al.  Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. , 2011, Journal of the American Academy of Dermatology.

[72]  M. Chance,et al.  The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation , 2011, Nature Immunology.

[73]  B. Kirby,et al.  Innate immunity in the pathogenesis of psoriasis , 2011, Archives of Dermatological Research.

[74]  A. Riaz,et al.  Metronidazole and the immune system. , 2011, Die Pharmazie.

[75]  J. Laman,et al.  Elevated levels of tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β and IL‐10 in hidradenitis suppurativa skin: a rationale for targeting TNF‐α and IL‐1β , 2011, The British journal of dermatology.

[76]  G. Basso,et al.  Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells , 2011, Leukemia.

[77]  B. Stausbøl‐Grøn,et al.  Successful use of infliximab in macrophage activation syndrome with severe CNS involvement , 2011, Scandinavian journal of rheumatology.

[78]  A. Shalita,et al.  Clinical applications of non-antimicrobial tetracyclines in dermatology. , 2011, Pharmacological research.

[79]  H. Volk,et al.  Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa , 2011, The Journal of Immunology.

[80]  G. Cocco,et al.  Colchicine in clinical medicine. A guide for internists. , 2010, European journal of internal medicine.

[81]  J. Jais,et al.  Efficacy of Rifampin-Moxifloxacin-Metronidazole Combination Therapy in Hidradenitis Suppurativa , 2010, Dermatology.

[82]  P. Teeling,et al.  Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis , 2010, PloS one.

[83]  Yan Shen,et al.  γ-Secretase Gene Mutations in Familial Acne Inversa , 2010, Science.

[84]  K. Harding,et al.  Non-healing is associated with persistent stimulation of the innate immune response in chronic venous leg ulcers. , 2010, Journal of dermatological science.

[85]  J. Szepietowski,et al.  Psychophysical aspects of hidradenitis suppurativa. , 2010, Acta dermato-venereologica.

[86]  Y. Troyanov,et al.  Macrophage Activation Syndrome Treated with Anakinra , 2010, The Journal of Rheumatology.

[87]  Dan R. Littman,et al.  Th17 and Regulatory T Cells in Mediating and Restraining Inflammation , 2010, Cell.

[88]  J. Alcorn,et al.  TH17 cells in asthma and COPD. , 2010, Annual review of physiology.

[89]  F. Kerdel,et al.  Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. , 2010, Journal of the American Academy of Dermatology.

[90]  B. Bergmans,et al.  γ-secretases: from cell biology to therapeutic strategies , 2010, The Lancet Neurology.

[91]  G. Jemec,et al.  Resorcinol peels as a possible self‐treatment of painful nodules in hidradenitis suppurativa , 2010, Clinical and experimental dermatology.

[92]  C. Zouboulis,et al.  Comorbidities of hidradenitis suppurativa (acne inversa) , 2010, Dermato-endocrinology.

[93]  H. Chi,et al.  Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. , 2009, Cytokine.

[94]  G. Jemec,et al.  Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. , 2009, Acta dermato-venereologica.

[95]  J. Lapins,et al.  Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity , 2009, The British journal of dermatology.

[96]  O. Faye,et al.  Combination Therapy with Clindamycin and Rifampicin for Hidradenitis Suppurativa: A Series of 116 Consecutive Patients , 2009, Dermatology.

[97]  G. Jemec,et al.  The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa , 2009, Dermatology.

[98]  Lisa C. Zaba,et al.  IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.

[99]  D. Eisen,et al.  Hidradenitis suppurativa: a comprehensive review. , 2009, Journal of the American Academy of Dermatology.

[100]  B. Blom,et al.  From interleukin‐23 to T‐helper 17 cells: human T‐helper cell differentiation revisited , 2008, Immunological reviews.

[101]  A. Ramanan,et al.  A case of macrophage activation syndrome successfully treated with anakinra , 2008, Nature Clinical Practice Rheumatology.

[102]  B. Strooper,et al.  Presenilins: members of the gamma-secretase quartets, but part-time soloists too. , 2008, Physiology.

[103]  C. Lam,et al.  Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. , 2008, Clinical immunology.

[104]  N. Yawalkar,et al.  Toll‐like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C‐type lectin receptor , 2008, The British journal of dermatology.

[105]  R. Kandel,et al.  TNF-&agr; Induces MMP2 Gelatinase Activity and MT1-MMP Expression in an In Vitro Model of Nucleus Pulposus Tissue Degeneration , 2008, Spine.

[106]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[107]  G. Yosipovitch,et al.  Obesity and the skin: skin physiology and skin manifestations of obesity. , 2007, Journal of the American Academy of Dermatology.

[108]  Özden Özyemişçi-Taşkıran,et al.  A hidradenitis suppurativa related SAPHO case associated with features resembling spondylarthropathy and proteinuria , 2007, Clinical Rheumatology.

[109]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[110]  E. Nishida,et al.  Notch Signaling Suppresses p38 MAPK Activity via Induction of MKP-1 in Myogenesis* , 2007, Journal of Biological Chemistry.

[111]  E. Giamarellos‐Bourboulis,et al.  Altered innate and adaptive immune responses in patients with hidradenitis suppurativa , 2007, The British journal of dermatology.

[112]  S. Crowe,et al.  Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV‐related diseases , 2006, Journal of leukocyte biology.

[113]  K. Mills,et al.  A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis , 2006, The Journal of experimental medicine.

[114]  E. Wickham,et al.  Dermatology of androgen-related disorders. , 2006, Clinics in dermatology.

[115]  M. Komine,et al.  Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A , 2006, The British journal of dermatology.

[116]  C. Griffiths,et al.  Clindamycin and rifampicin combination therapy for hidradenitis suppurativa , 2006, The British journal of dermatology.

[117]  J. Rodríguez-Sánchez,et al.  TNFα production to TLR2 ligands in active IBD patients , 2006 .

[118]  R. Fleischmajer,et al.  Tetracyclines: nonantibiotic properties and their clinical implications. , 2006, Journal of the American Academy of Dermatology.

[119]  S. Clark,et al.  Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin , 2006, Clinical and experimental dermatology.

[120]  A. Dalhoff.  Immunomodulatory Activities of Fluoroquinolones , 2005, Infection.

[121]  C. Evans,et al.  Pyoderma gangrenosum associated with hidradenitis suppurativa , 2005, Clinical and experimental dermatology.

[122]  V. Nizet,et al.  Keratinocyte Production of Cathelicidin Provides Direct Activity against Bacterial Skin Pathogens , 2005, Infection and Immunity.

[123]  Jenny Kim.  Review of the Innate Immune Response in Acne vulgaris: Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses , 2005, Dermatology.

[124]  K. Short,et al.  Vulval squamous cell carcinoma arising in chronic hidradenitis suppurativa , 2005, Clinical and experimental dermatology.

[125]  A. So,et al.  Toll-like receptor 2 and toll-like receptor 4 expression on CD64+ monocytes in rheumatoid arthritis: comment on the article by Iwahashi et al. , 2005, Arthritis and rheumatism.

[126]  R. de Waal Malefyt,et al.  IL‐12 and IL‐23: master regulators of innate and adaptive immunity , 2004, Immunological reviews.

[127]  Raphael Kopan,et al.  gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. , 2004, Developmental cell.

[128]  R. Finch,et al.  Immunomodulating Activity of Rifampicin , 2004, Journal of chemotherapy.

[129]  C. Whelan.  Metalloprotease inhibitors as anti-inflammatory agents: an evolving target? , 2004, Current opinion in investigational drugs.

[130]  B. Joffe,et al.  Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[131]  G. Bouma,et al.  The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.

[132]  B. Strauss,et al.  Matrix metalloproteinases: a therapeutic target in cardiovascular disease. , 2003, Current pharmaceutical design.

[133]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[134]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[135]  C. Antoni,et al.  Infliximab for psoriasis and psoriatic arthritis. , 2002, Clinical and experimental rheumatology.

[136]  G. Jemec.  Methotrexate is of limited value in the treatment of hidradenitis suppurativa , 2002, Clinical and experimental dermatology.

[137]  S. Szabo,et al.  The Transcription Factor T-bet Regulates Mucosal T Cell Activation in Experimental Colitis and Crohn's Disease , 2002, The Journal of experimental medicine.

[138]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[139]  B. Bresnihan,et al.  Targeting interleukin-1 in the treatment of rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[140]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[141]  G. Jemec,et al.  Morbidity in patients with hidradenitis suppurativa , 2001, The British journal of dermatology.

[142]  P. Fasseas,et al.  Hidradenitis suppurativa and acne conglobata associated with spondyloarthropathy. , 2001, The American journal of the medical sciences.

[143]  D. Kono,et al.  The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity , 2001, Arthritis research.

[144]  S. Hanauer,et al.  Infliximab in Crohn's disease: first anniversary clinical experience , 2000, American Journal of Gastroenterology.

[145]  J. Petres,et al.  Long‐Term Results of Wide Surgical Excision in 106 Patients with Hidradenitis Suppurativa , 2000, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[146]  J. Pelletier,et al.  Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[147]  R. Happle,et al.  Cigarette Smoking as a Triggering Factor of Hidradenitis suppurativa , 1999, Dermatology.

[148]  G. Jemec,et al.  Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. , 1998, Journal of the American Academy of Dermatology.

[149]  F. Balkwill,et al.  Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). , 1998, British Journal of Cancer.

[150]  Yulan He,et al.  IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. , 1998, Journal of immunology.

[151]  L. O’Driscoll,et al.  Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. , 1997, American journal of respiratory and critical care medicine.

[152]  J. B. Smith,et al.  Cigarette smoking and inflammatory skin disease. The good and the bad. , 1997, Archives of dermatology.

[153]  Yoshihiro Ohmori,et al.  Synergy between Interferon-γ and Tumor Necrosis Factor-α in Transcriptional Activation Is Mediated by Cooperation between Signal Transducer and Activator of Transcription 1 and Nuclear Factor κB* , 1997, The Journal of Biological Chemistry.

[154]  M. Hundeiker,et al.  Acne inversa (pyodermia fistulans sinifica) and smoking. , 1997, Journal of the American Academy of Dermatology.

[155]  E. Haddad,et al.  Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. , 1996, The Journal of pediatrics.

[156]  A. Wahba-Yahav.  Disease concomitance in psoriasis. , 1996, Journal of the American Academy of Dermatology.

[157]  G. Jemec,et al.  Histology of hidradenitis suppurativa. , 1996, Journal of the American Academy of Dermatology.

[158]  P. Shenefelt.  Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. , 1996, Cutis.

[159]  M. Gerig,et al.  A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.

[160]  A. Douglas-Jones,et al.  The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands , 1995, The British journal of dermatology.

[161]  D. Buckley,et al.  Cyclosporin-responsive hidradenitis suppurativa. , 1995, Journal of the Royal Society of Medicine.

[162]  B. Spiegelman,et al.  Tumor necrosis factor alpha inhibits signaling from the insulin receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[163]  J. Kremer,et al.  Methotrexate for Rheumatoid Arthritis , 1994 .

[164]  K. Radcliffe,et al.  Hidradenitis suppurativa. , 1991, Genitourinary medicine.

[165]  W. Bergfeld,et al.  Reticulate pigmented anomaly of the flexures (Dowling-Degos disease): a case report associated with hidradenitis suppurativa and squamous cell carcinoma. , 1990, Cutis.

[166]  M. G. Cook,et al.  Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands , 1990, The British journal of dermatology.

[167]  H. Ziegler,et al.  MACROPHAGES AS TARGETS FOR INHIBITION BY CYCLOSPORINE , 1989, Transplantation.

[168]  B. J. Harrison,et al.  Endocrine basis for the clinical presentation of hidradenitis suppurativa , 1988, The British journal of surgery.

[169]  B. J. Harrison,et al.  Recurrence after surgical treatment of hidradenitis suppurativa. , 1987, British medical journal.

[170]  C. Cluff,et al.  Cyclosporine inhibits macrophage-mediated antigen presentation. , 1986, Journal of immunology.

[171]  B. Kahan,et al.  ALTERATIONS IN RAT PULMONARY MACROPHAGE FUNCTION BY THE IMMUNOSUPPRESSIVE AGENTS CYCLOSPORINE, AZATHIOPRINE, AND PREDNISOLONE , 1983, Transplantation.

[172]  O. Clemmensen.  Topical Treatment of Hidradenitis Suppurativa with Clindamycin , 1983, International journal of dermatology.

[173]  E. Unanue,et al.  Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. , 1982, Journal of immunology.

[174]  A. Wahba,et al.  Therapeutic trials with oral colchicine in psoriasis. , 1980, Acta dermato-venereologica.

[175]  R. Williamson,et al.  On the Treatment of Glycosuria and Diabetes Mellitus with Sodium Salicylate , 1901, British medical journal.

[176]  M. Netea,et al.  Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. , 2016, JAMA dermatology.

[177]  C. Zouboulis,et al.  Endocrinologic Aspects of Hidradenitis Suppurativa. , 2016, Dermatologic clinics.

[178]  J. Ingram.  The Genetics of Hidradenitis Suppurativa. , 2016, Dermatologic clinics.

[179]  P. A. Crawford,et al.  The ketone metabolite β-hydroxybutyrate blocks NLRP 3 inflammasome – mediated inflammatory disease , 2015 .

[180]  N. Parameswaran,et al.  Tumor necrosis factor-α signaling in macrophages. , 2010, Critical reviews in eukaryotic gene expression.

[181]  G. Kalliolias,et al.  The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. , 2008, Expert opinion on investigational drugs.

[182]  J. Rodríguez-Sánchez,et al.  TNF alpha production to TLR2 ligands in active IBD patients. , 2006, Clinical immunology.

[183]  M. Suarez‐Almazor,et al.  Azathioprine for rheumatoid arthritis. , 2000, The Cochrane database of systematic reviews.

[184]  G. Jemec,et al.  The bacteriology of hidradenitis suppurativa. , 1996, Dermatology.